Tocilizumab treatment in a patient suffering from rheumatoid arthritis and concomitant chronic hepatitis C infection

Rheumatology (United Kingdom)

Volumn 51, Issue 8, 2012, Pages 1520-1521

  Dragonas, Charalampos ^a   Ehrenstein, Boris ^a   Fleck, Martin ^a,b  

^a Asklepios Clinic   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; METHOTREXATE; PREDNISOLONE; RHEUMATOID FACTOR; TOCILIZUMAB; VIRUS RNA;

ADULT; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; CONCURRENT INFECTION; CORTICOSTEROID THERAPY; DISEASE CONTROL; DRUG SAFETY; DRUG WITHDRAWAL; ECHOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; FOLLOW UP; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LEUKOCYTE COUNT; LIVER FUNCTION; LIVER FUNCTION TEST; LIVER PARENCHYMA; MALE; PRIORITY JOURNAL; PUSTULAR PSORIASIS; RHEUMATOID ARTHRITIS; TREATMENT DURATION; VIRUS LOAD;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; PREDNISOLONE; RNA, VIRAL; VIRAL LOAD;

EID: 84865163389     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes051     Document Type: Letter

References (10)

1. Nagashima T, Maruyama A, Kamata Y, Minota S. Unchanged serum viral load and liver function during tocilizumab treatment in a patient with rheumatoid arthritis and hepatitis C virus infection. Rheumatol Int 2011, Advance Access published July 23 2011. doi 10.1007/ s00296-011-2060-2.
2. Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum 2000;43:1431-42.
3. Ezzat WM, Raslan HM, Aly AA et al. Anti-cyclic citrullinated peptide antibodies as a discriminating marker between rheumatoid arthritis and chronic hepatitis C-related polyarthropathy. Rheumatol Int 2011;31:65-9.
4. Brunasso AM, Puntoni M, Gulia A, Massone C. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. Rheumatology 2011;50:1700-11.
5. Mok MY, Ng WL, Yuen MF, Wong RW, Lau CS. Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis. Clin Exp Rheumatol 2000;18:363-8.
6. Manna R, Verrecchia E, Fonnesu C et al. Cyclosporine A: good response for patients affected by autoimmune disorders and HCV infection? Eur Rev Med Pharmacol Sci 2009;13(Suppl. 1):63-9.
7. Berenguer M, Royuela A, Zamora J. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl 2007;13:21-9.
8. Ciesek S, Steinmann E, Iken M et al. Glucocorticosteroids increase cell entry by hepatitis C virus. Gastroenterology 2010;138:1875-84.
9. Streetz KL, Luedde T, Manns MP, Trautwein C. Interleukin and liver regeneration. Gut 2000;47:309-12.
10. Campbell L, Chen C, Bhagat SS, Parker RA, östör AJ. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology 2011;50:552-62.